138 related articles for article (PubMed ID: 37244842)
1. Quantifying variation in home spirometry in people with cystic fibrosis during baseline health, and associations with clinical outcomes.
Thornton CS; Magaret AS; Carmody LA; Kalikin LM; Simon RH; LiPuma JJ; Caverly LJ
J Cyst Fibros; 2024 Mar; 23(2):321-328. PubMed ID: 37244842
[TBL] [Abstract][Full Text] [Related]
2. The effect of oral and intravenous antimicrobials on pulmonary exacerbation recovery in cystic fibrosis.
VanDevanter EJ; Heltshe SL; Skalland M; Lechtzin N; Nichols D; Goss CH
J Cyst Fibros; 2021 Nov; 20(6):932-936. PubMed ID: 33685776
[TBL] [Abstract][Full Text] [Related]
3. Lung function changes before and after pulmonary exacerbation antimicrobial treatment in cystic fibrosis.
Wagener JS; VanDevanter DR; Konstan MW; Pasta DJ; Millar SJ; Morgan WJ
Pediatr Pulmonol; 2020 Mar; 55(3):828-834. PubMed ID: 31746561
[TBL] [Abstract][Full Text] [Related]
4. Adjunctive Systemic Corticosteroids for Pulmonary Exacerbations of Cystic Fibrosis.
McElvaney OJ; Heltshe SL; Odem-Davis K; West NE; Sanders DB; Fogarty B; VanDevanter DR; Flume PA; Goss CH
Ann Am Thorac Soc; 2024 May; 21(5):716-726. PubMed ID: 38096105
[No Abstract] [Full Text] [Related]
5. Re-examining baseline lung function recovery following IV-treated pulmonary exacerbations.
Heltshe SL; Russell R; VanDevanter DR; Sanders DB
J Cyst Fibros; 2023 Sep; 22(5):864-867. PubMed ID: 36803635
[TBL] [Abstract][Full Text] [Related]
6. Association Between Number of Intravenous Antipseudomonal Antibiotics and Clinical Outcomes of Pediatric Cystic Fibrosis Pulmonary Exacerbations.
Cogen JD; Faino AV; Onchiri F; Hoffman LR; Kronman MP; Nichols DP; Rosenfeld M; Gibson RL
Clin Infect Dis; 2021 Nov; 73(9):1589-1596. PubMed ID: 34100912
[TBL] [Abstract][Full Text] [Related]
7. Home-spirometry exacerbation profiles in children with cystic fibrosis.
Bouteleux B; Beaufils F; Fayon M; Bui S
Pediatr Pulmonol; 2024 Mar; 59(3):552-561. PubMed ID: 38014613
[TBL] [Abstract][Full Text] [Related]
8. Continuous glucose monitoring indices predict poor FEV
Pallin M; Kumar S; Daley C; Dawadi S; Leong P; Carr E; Soldatos G
J Cyst Fibros; 2021 Sep; 20(5):785-791. PubMed ID: 33781701
[TBL] [Abstract][Full Text] [Related]
9. Correspondence between lung function and symptom measures from the Cystic Fibrosis Respiratory Symptom Diary-Chronic Respiratory Infection Symptom Score (CFRSD-CRISS).
Gold LS; Patrick DL; Hansen RN; Goss CH; Kessler L
J Cyst Fibros; 2019 Nov; 18(6):886-893. PubMed ID: 31126901
[TBL] [Abstract][Full Text] [Related]
10. A comparison of clinic and home spirometry as longtudinal outcomes in cystic fibrosis.
Paynter A; Khan U; Heltshe SL; Goss CH; Lechtzin N; Hamblett NM
J Cyst Fibros; 2022 Jan; 21(1):78-83. PubMed ID: 34474987
[TBL] [Abstract][Full Text] [Related]
11. Impact of lumacaftor/ivacaftor and tezacaftor/ivacaftor on treatment response in pulmonary exacerbations of F508del/F508del cystic fibrosis.
McElvaney OJ; Heltshe SL; Odem-Davis K; West NE; Sanders DB; Fogarty B; VanDevanter DR; Flume PA; Goss CH;
J Cyst Fibros; 2023 Sep; 22(5):875-879. PubMed ID: 37407341
[TBL] [Abstract][Full Text] [Related]
12. Patients with cystic fibrosis and advanced lung disease benefit from lumacaftor/ivacaftor treatment.
Ejiofor LCK; Mathiesen IHM; Jensen-Fangel S; Olesen HV; Skov M; Philipsen LKD; Pedersen CL; Pressler T
Pediatr Pulmonol; 2020 Dec; 55(12):3364-3370. PubMed ID: 32897653
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of lumacaftor/ivacaftor combination therapy in patients with cystic fibrosis homozygous for Phe508del CFTR by pulmonary function subgroup: a pooled analysis.
Elborn JS; Ramsey BW; Boyle MP; Konstan MW; Huang X; Marigowda G; Waltz D; Wainwright CE;
Lancet Respir Med; 2016 Aug; 4(8):617-626. PubMed ID: 27298017
[TBL] [Abstract][Full Text] [Related]
14. Rationale and design of a randomized trial of home electronic symptom and lung function monitoring to detect cystic fibrosis pulmonary exacerbations: the early intervention in cystic fibrosis exacerbation (eICE) trial.
Lechtzin N; West N; Allgood S; Wilhelm E; Khan U; Mayer-Hamblett N; Aitken ML; Ramsey BW; Boyle MP; Mogayzel PJ; Goss CH
Contemp Clin Trials; 2013 Nov; 36(2):460-9. PubMed ID: 24055998
[TBL] [Abstract][Full Text] [Related]
15. VOCAL: An observational study of ivacaftor for people with cystic fibrosis and selected non-G551D-CFTR gating mutations.
Simmonds NJ; van der Ent CK; Colombo C; Kinnman N; DeSouza C; Thorat T; Chew ML; Chandarana K; Castellani C
J Cyst Fibros; 2023 Jan; 22(1):124-131. PubMed ID: 35613999
[TBL] [Abstract][Full Text] [Related]
16. Electronic home monitoring of children with cystic fibrosis to detect and treat acute pulmonary exacerbations and its effect on 1-year FEV
Yanaz M; Yilmaz Yegit C; Gulieva A; Kalyoncu M; Selcuk M; Uzunoglu B; Tastan G; Ergenekon AP; Gokdemir Y; Erdem Eralp E; Karakoc F; Karadag B
J Cyst Fibros; 2024 Mar; 23(2):329-333. PubMed ID: 37748990
[TBL] [Abstract][Full Text] [Related]
17. Improved recognition of lung function decline as signal of cystic fibrosis pulmonary exacerbation: a Cystic Fibrosis Learning Network Innovation Laboratory quality improvement initiative.
List R; Solomon G; Bichl S; Horton BJ; Shen S; Corcoran B; Sadeghi H; Britto MT; Ren C; Albon D;
BMJ Open Qual; 2023 Dec; 12(4):. PubMed ID: 38154821
[TBL] [Abstract][Full Text] [Related]
18. Mucus plugging, air trapping, and bronchiectasis are important outcome measures in assessing progressive childhood cystic fibrosis lung disease.
Robinson TE; Goris ML; Moss RB; Tian L; Kan P; Yilma M; McCoy KS; Newman B; de Jong PA; Long FR; Brody AS; Behrje R; Yates DP; Cornfield DN
Pediatr Pulmonol; 2020 Apr; 55(4):929-938. PubMed ID: 31962004
[TBL] [Abstract][Full Text] [Related]
19. Impact of COVID-19 on Lung Disease in People with Cystic Fibrosis: A 6-Month Follow-Up Study on Respiratory Outcomes.
Medino P; Alicandro G; Rosazza C; Ciciriello F; Gramegna A; Biffi A; Daccò V; Lucidi V; Cipolli M; Boraso M; Nazzari E; Colombo C
Biomedicines; 2022 Nov; 10(11):. PubMed ID: 36359291
[TBL] [Abstract][Full Text] [Related]
20. Unsupervised home spirometry is not equivalent to supervised clinic spirometry in children and young people with cystic fibrosis: Results from the CLIMB-CF study.
Edmondson C; Westrupp N; Short C; Seddon P; Olden C; Wallis C; Brodlie M; Baxter F; McCormick J; MacFarlane S; Brooker R; Connon M; Ghayyda S; Blaikie L; Thursfield R; Brown L; Price A; Fleischer E; Hughes D; Donnelly C; Rosenthal M; Wallenburg J; Brownlee K; Alton EWFW; Bush A; Davies JC
Pediatr Pulmonol; 2023 Oct; 58(10):2871-2880. PubMed ID: 37503909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
